Kiniksa Pharmaceuticals International (KNSA) EPS (Basic) (2017 - 2026)

Kiniksa Pharmaceuticals International has reported EPS (Basic) for 10 years, with the latest figure at $0.3 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Basic) rose 150.0% year-over-year to $0.3; the trailing twelve-month figure through Mar 2026 stood at $0.98 (up 508.33% YoY), and the FY2025 full-year result was $0.8, up 233.33% from the prior year.
• EPS (Basic) for Q1 2026 stood at $0.3, up from $0.19 in the prior quarter.
• The five-year high for EPS (Basic) was $3.23 in Q3 2022, with the low at -$0.36 in Q1 2022.
• Historically, EPS (Basic) has averaged $0.2 across 5 years, with a median of $0.06 in 2022.
• Annual changes were most pronounced in 2022 — EPS (Basic) soared 834.09% — and 2024, when it tumbled 133.33%.
• Kiniksa Pharmaceuticals International's EPS (Basic) stood at $0.06 in 2022, then jumped by 500.0% to $0.36 in 2023, then sank by 133.33% to -$0.12 in 2024, then jumped by 258.33% to $0.19 in 2025, then soared by 57.89% to $0.3 in 2026.
• The last three EPS (Basic) figures came in at $0.3 (Q1 2026), $0.19 (Q4 2025), and $0.25 (Q3 2025), per Business Quant data.